ADPKD mostly presents in adulthood, whereas ARPKD is usually detected during antenatal screening or as a neonate. This article will focus on key points to understand and consider for the holistic management of PKD.Soo OhRoyal Stoke HospitalInnov A i T...
Read the full KDIGO 2024 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Diseasehere. Acute Kidney Injury Acute kidney injury (AKI) is a sudden loss of kidney function10 In recent years, AKI has gained increasing recognition as a major risk factor for...
The Tolvap- tan Efficacy and Safety in Management of PKD and Outcomes (TEMPO) program is currently active[74, 75]. Phase 2a studies to determine the response to increasing doses of tolvaptan (15, 30, 60, and 120 mg) in patients with ADPKD and normal renal function have been completed[...
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary Kidney International, Volume 107, Issue 2, February 2025, Pages 234-254 Vicente E. Torres, Curie Ahn, Thijs R.M. Barten, Godela Brosnahan...
Thus, the genetic test must be used with clinical diagnostics, such as ultrasound and blood chemistries, to develop a health management plan for a PKD-positive cat. Hypertrophic cardiomyopathy is a more complex situation. Cats can have one or two copies of the DNA disease-causing variant; ...
U. et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management – KDIGO consensus report. Kidney Int. 88, 676–683 (2015). This consensus document established the gene-based, unifying terminology for ADTKD as well as the clinical criteria and principles of...
The consortium hopes that this information will provide clinicians with a strong evidence base for therapeutic decisions and patient management. Reference 1. Ebner, K., et al. (2015) “Rationale, design and objectives of ARegPKD, a European ARPKD registry study,” BioMed Central Nephrolog...
Leveraging prognostic estimates to guide therapy could help clinicians to prescribe CKD-related therapies to those who are most likely to benefit from their use. Risk-based CKD management thus aligns patient risk and care, allowing the prioritization of absolute benefit in determining therapeutic ...
Tan YM, Ooi LLPJ, Mack POP. Current status in the surgical management of adult polycystic liver disease. Ann Acad Med Singapore. 2002;31(2):217–22. CASPubMedGoogle Scholar Garcea G, Rajesh A, Dennison AR. Surgical management of cystic lesions in the liver. ANZ J Surg. 2013;83(7–8...
Potential advantages of acute kidney injury management by mesenchymal stem cells. World J. Stem Cells 6, 644–650 (2014). Article PubMed PubMed Central Google Scholar Camussi, G., Deregibus, M. C., Bruno, S., Cantaluppi, V. & Biancone, L. Exosomes/microvesicles as a mechanism of ...